Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
NCT07407283Phase 2Recruiting
- Sponsor
- Hengrui
- Start
- Apr 2026
- Primary completion
- Nov 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-4394 in prostate cancer (PCa), sponsored by Hengrui. Started Apr 2026; status: recruiting.
02
Drugs
SHR-4394
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07407283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07407283.